This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Mallal S, Phillips E, Carosi G, Molina J-M, Workman C, Tomažič J, Jägel-Guedes E, Rugina S, Kozyrev O, Flores Cid J, Hay P, Nolan D, Hughes S, Hughes A, Thorborn D, Benbow A.PREDICT-1: a novel randomised prospective study to determine the clinical utility of HLA-B*5701 screening to reduce abacavir hypersensitivity in HIV-1 infected subjects (study CNA106030). 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention: Late Breaker Abstracts: 27, 22 Jul 2007
Kiertiburanakul S, Sungkanuparph S, Charoenyingwattana A, Mahasirimongkol S, Sura T, Chantratita W.Risk factors for nevirapine-associated rash among HIV-infected patients with low CD4 cell counts in resource-limited setting. 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention: 51, 22 Jul 2007
Villar Del Saz S, Milinkovic A, Domingo P, Podzamczer D, Gonzalez A, Ocaña I, de Lazzari E, Knobel H, Gatell JM, Clotet B, Ribera E.Tolerability of emtricitabine in HIV infected subjects who switch from lamivudine to FTC. 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention: 52 (plus poster) abstr. MOPEB012, 22 Jul 2007
Walmsley S, Bredeek U, Avihingsanon A, Slim J, C.Evaluation of the impact of highly active antiretroviral therapy on lipid profiles - data from the 24-week interim analysis of the Gemini Study: saquinavir/r BID vs lopinavir/r BID plus emtricitabine/tenofovir QD in ARV-naive HIV-1-infected patients. 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention: 141 (plus poster) abstr. TUPEB069, 22 Jul 2007
Rights and permissions
About this article
Cite this article
ADR news from IAS. React. Wkly. 1165, 4 (2007). https://doi.org/10.2165/00128415-200711650-00010
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128415-200711650-00010